Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB to acquire Zogenix - Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and expanding clinical development pipeline of epilepsy and rare dise...
Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study - The BE MOBILE 1 study met the primary and all ranked secondary endpoints, showing that bimekizumab improved outcomes in patients with active non-radiographic axial spondyloarthr...
Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial - BE MOBILE 2 is a Phase 3 study evaluating the efficacy and safety of bimekizumab in the treatment of patients with active ankylosing spondylitis - The trial met the primary endpoint and all r...
UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care - 17 scientific presentations illustrate and reinforce UCB's commitment to improving the lives of people living with e...
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease -- UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two innovative and potentially disease-modifying investigational assets in...
Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms -- The BE OPTIMAL study met the primary endpoint and all ranked secondary endpoints with statistical significance -- The study used t...
UCB Showcases Key Rheumatology Data at ACR Convergence 2021 -- Eleven abstracts across UCB's rheumatology portfolio, including investigational bimekizumab and CIMZIA® (certolizumab pegol), underscore UCB's dedication to rheumatology -- Long-term three-year data from Pha...
Sharecare and UCB to present on future of decentralized clinical research at 2021 CNS Summit Spotlight session highlighting Sharecare's efforts to advance real-world relevance, equity, and data integrity in clinical research scheduled for Monday, Nov. 8 at 2 p.m. EST PR News...
UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab - ImageBiopsy Lab will further develop and launch an AI-based fracture identification tool based on UCB-developed BoneBot AI technology which detects the presence of "silent" or asym...
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab - The U.S. FDA has informed UCB via letter that the Agency was unable to complete review of the BLA for bimekizumab by the PDUFA date and is deferring action on the application - The Agency cite...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...